

Name: Professor Joe Duffy

Address: St Vincent's University Hospital/University College Dublin, Dublin

E-mail address: Michael.J.Duffy@ucd.ie

General research interests: Cancer biomarkers, novel molecularly targeting therapies for breast cancer (targeting mutant p53, vitamin D receptor), Preparing guidelines for clinical uses of cancer biomarkers.

Publications: 2013-2017

1. Duffy MJ, Crown J. Companion biomarkers: paving the pathway to personalized treatment for cancer. *Clin Chem*. 2013;59:1447-56.
2. Canonici A, Gijzen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. *Oncotarget*. 2013;4:1592.
3. Saldova R, Struwe WB, Wynne K, Elia G, Duffy MJ, Rudd PM. Exploring the glycosylation of serum CA125. *Int J Mol Sci* 2013;14:15636-54.
4. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L, Sturgeon C. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. *Int J Cancer* 2014;134:2513-22.
5. Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg Á, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, Parsons M, Bartsch JW, Sonenshein GE. ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. *EMBO Mol Med*. 2014;6:278-94.
6. O'Hurley G, Daly E, O'Grady A, Cummins R, Quinn C, Flanagan L, Pierce A, Fan Y, Lynn MA, Rafferty M, Fitzgerald D, Pontén F, Duffy MJ, Jirstrom K, Kay EW, Gallagher WM. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. *Histopathology* 2014;64:660-70.
7. Duffy MJ, Crown J. Precision Treatment for Cancer: Role of Prognostic and Predictive Markers. *Crit Rev Clin Lab Sci* 2014;51:30-45.
8. Gaule PB, Crown J, O'Donovan N, Duffy MJ. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? *Expert Opin Ther Targets*. 2014;18:999-1009.
9. Duffy MJ, Crown J, Mullooly M. ADAM10 and ADAM17: New players in trastuzumab resistance. *Oncotarget*. 2014;5(22):10963-4.
10. Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM. p53 as a target for the treatment of cancer. *Cancer Treat Rev* 2014;40:1153-60.
11. Duffy MJ, McGowan P, Harbeck N, Thommsen C, Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. *Breast Cancer Res* 2014;16:428.

12. Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM. p53 as a target for the treatment of cancer. *Cancer Treat Rev.* 2014;40:1153-60.
13. Duffy MJ. Personalized treatment for patients with colorectal cancer: role of biomarkers. *Biomark Med* 2015;9:337-47.
14. Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM. Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers. *Clin Chem* 2015;61:809-820.
15. Caiazza F, McGowan PM, Mullooly M, Murray A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J, Duffy MJ. Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. *Br J Cancer* 2015;112:1895-903.
16. Caiazza F, McGowan PM, Mullooly M, Murray A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J, Duffy MJ. Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. *Br J Cancer* 2015;112:1895-903.
17. Mullooly M, McGowan PM, Kennedy SA, Madden SF, Crown J, O' Donovan N, Duffy MJ. ADAM10: a new player in breast cancer progression? *Br J Cancer.* 2015;113:945-51.
18. Duffy MJ, Walsh S, McDermott EW, Crown J. Biomarkers in Breast Cancer: Where Are We and Where Are We Going” *Adv Clin Chem.* 2015;71:1-23.
19. Duffy MJ. Use of Biomarkers in Screening for Cancer. *Adv Exp Med Biol.* 2015;867:27-39.
20. Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated guidelines from the European Group on Tumor Markers. *Int J Gynecol Cancer.* 2016;26:43-51.
21. Mullooly M, McGowan PM, Crown J, Duffy MJ. The ADAMs family of proteases as targets for the treatment of cancer. *Cancer Biol Ther.* 2016 Aug 2;17(8):870-80.
22. Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O'Donovan N, Crown J, Duffy MJ. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells. *Endocr Relat Cancer.* 2016 Apr;23(4):323-34.
23. Duffy MJ, O'Donovan N, McDermott E, Crown J. Validated biomarkers: The key to precision treatment in patients with breast cancer. *Breast.* 2016 Oct;29:192-201.
24. Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J, Duffy MJ. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? *Int J Cancer.* 2017 Jan 1;140(1):234-246.
25. Murray A, Madden SF, Synnott NC, Klinger R, O'Connor D, O'Donovan N, Gallagher W, Crown J, Duffy MJ. Vitamin D receptor as a target for breast cancer therapy. *Endocr Relat Cancer.* 2017 Apr;24(4):181-195.

26. Duffy MJ, McDermott EW, Crown J. Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy. *Clin Chem.* 2017 Apr;63(4):804-806.
27. Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). *Eur J Cancer.* 2017 Apr;75:284-298.
28. Duffy MJ, Murray A, Synnott NC, O'Donovan N, Crown J. Vitamin D analogues: Potential use in cancer treatment. *Crit Rev Oncol Hematol.* 2017 Apr;112:190-197.
29. Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. *Eur J Cancer.* 2017 Sep;83:258-265.
30. Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. *Semin Cancer Biol.* 2017 Sep 4. pii: S1044-579X(17)30052-4. doi: 10.1016/j.semcancer.2017.08.010. [Epub ahead of print]